Clavis Pharma business strategy is to develop of a strong pipeline of proprietary new and improved cancer drugs and commercialise these products through strategic alliances and partnerships with experienced oncology businesses and, where and when commercially appropriate, by establishing its own sales and marketing capabilities.
In November 2009, Clavis Pharma and Clovis Oncology signed an agreement for the further development and commercialisation of CP-4126 in pancreatic cancer and other solid tumours for North & South America and for Europe.
Clavis Pharma is open to discuss out-licensing and strategic collaborations with potential partners in the field of cancer therapeutics and non-core assets (anti-viral drugs and anti-inflammatory drugs) where its LVT technology may lead to the development of new and improved drugs.
Data and further details are available upon request. For further inquiries, please send an email to info@clavispharma.com or contact:
Jan Alfheim, Chief Business Officer
Tel.: +47 24 11 09 55
Mob.: +47 46 44 00 45
email: jan.alfheim@clavispharma.com
